Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli.
Previous studies showed that infusion of C4b-binding protein with sublethal Escherichia coli (E. coli) in the primate produced a consumptive coagulopathy followed by microvascular thrombosis and renal failure. The first objective of this study was to characterize the pathophysiology and mechanism of this phenomena following infusion of both these agents with emphasis on defining the role of free protein S. The second objective was to examine the relevance of this model to the hemolytic uremic syndrome. Infusion of C4b-binding protein alone reduced free protein S and decreased platelet concentration to 20% of baseline, whereas infusion of the C4b-binding protein/protein S complex did not. There was no activation of other inflammatory or coagulant factors. Infusion of sublethal E coli alone produced a transient inflammatory response with no reduction of free protein S. However, coinfusion of C4b-binding protein with sublethal E coli reduced free protein S and produced a thrombocytopenia, anemia, and a microvascular thrombotic response, whereas infusion of the C4b-binding protein/protein S complex with sublethal E coli did not. Studies comparing the effects of neutralizing (S-163) and nonneutralizing (S-145) antibodies with protein S coinfused with sublethal E coli produced similar contrasting results. Therefore, we concluded that neutralization of free protein S, and not some other property of C4b-binding protein influenced by protein S, accounted for this microvascular thrombotic response. This response is similar to the hemolytic uremic syndrome characterized by thrombocytopenia, anemia, shistocytosis, and renal glomerular thrombosis with uremia. Comparison of the respective renal histopathologic appearance supports this conclusion. This raises the possibility that inhibition of protein S activity (possibly by one of the forms of C4b-binding proteins) might be one of the factors contributing to microvascular thrombotic disorder, such as the hemolytic uremic syndrome.
Taylor
F B
FB
Oklahoma Medical Research Foundation, Program of Cardiovascular Biology, Oklahoma City 73104, USA.
Dahlback
B
B
Chang
A C
AC
Lockhart
M S
MS
Hatanaka
K
K
Peer
G
G
Esmon
C T
CT
D000818:Animals; D001777:Blood Coagulation / Q000502:physiology*; D001792:Blood Platelets / Q000187:drug effects; D002352:Carrier Proteins / Q000494:pharmacology / Q000502:physiology*; D003169:Complement Inactivator Proteins; D004926:Escherichia coli; D005340:Fibrinogen / Q000378:metabolism; D006023:Glycoproteins; D006400:Hematocrit; D006463:Hemolytic-Uremic Syndrome / Q000473:pathology; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D010215:Papio / Q000097:blood; D010976:Platelet Count; D017293:Protein S / Q000494:pharmacology / Q000502:physiology*
D002352:Carrier Proteins; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D017293:Protein S; D005340:Fibrinogen